CompletedPhase 1NCT04768985

Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule

Studying Catastrophic antiphospholipid syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AstraZeneca
Principal Investigator
Ronald Goldwater, MD
Parexel Early Phase Clinical Unit Baltimore Harbor Hospital 3001 South Hanover St. Baltimore, MD 21225 USA
Intervention
Treatment A: Acalabrutinib tablet(drug)
Enrollment
66 enrolled
Eligibility
18-55 years · All sexes
Timeline
20212021

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04768985 on ClinicalTrials.gov

Other trials for Catastrophic antiphospholipid syndrome

Additional recruiting or active studies for the same condition.

See all trials for Catastrophic antiphospholipid syndrome

← Back to all trials